michael Hutchinson
michael Hutchinson
E-mailová adresa ověřena na: - Domovská stránka
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ...
Annals of neurology 69 (2), 292-302, 2011
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ...
New England Journal of Medicine 354 (9), 899-910, 2006
Rate of pregnancy-related relapse in multiple sclerosis
C Confavreux, M Hutchinson, MM Hours, P Cortinovis-Tourniaire, ...
New England Journal of Medicine 339 (5), 285-291, 1998
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ...
New England Journal of Medicine 367 (12), 1087-1097, 2012
Differential diagnosis of suspected multiple sclerosis: a consensus approach
DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ...
Multiple Sclerosis Journal 14 (9), 1157-1174, 2008
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post‐partum relapse
S Vukusic, M Hutchinson, M Hours, T Moreau, P Cortinovis‐Tourniaire, ...
Brain 127 (6), 1353-1360, 2004
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing …
E Havrdova, S Galetta, M Hutchinson, D Stefoski, D Bates, CH Polman, ...
The Lancet Neurology 8 (3), 254-260, 2009
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL
PA Calabresi, G Giovannoni, C Confavreux, SL Galetta, E Havrdova, ...
Neurology 69 (14), 1391-1403, 2007
Translation initiator EIF4G1 mutations in familial Parkinson disease
MC Chartier-Harlin, JC Dachsel, C Vilariño-Güell, SJ Lincoln, F Leprêtre, ...
The American Journal of Human Genetics 89 (3), 398-406, 2011
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
DH Miller, D Soon, KT Fernando, DG MacManus, GJ Barker, TA Yousry, ...
Neurology 68 (17), 1390-1401, 2007
Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody
M Hutchinson, P Waters, J McHugh, G Gorman, S O’riordan, S Connolly, ...
Neurology 71 (16), 1291-1292, 2008
New perspectives in the natural history of multiple sclerosis
H Tremlett, Y Zhao, P Rieckmann, M Hutchinson
Neurology 74 (24), 2004-2015, 2010
Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia
N Fonknechten, D Mavel, P Byrne, CS Davoine, C Cruaud, D Boentsch, ...
Human molecular genetics 9 (4), 637-644, 2000
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
M Hutchinson, L Kappos, PA Calabresi, C Confavreux, G Giovannoni, ...
Journal of neurology 256, 405-415, 2009
Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome
S Hanein, E Martin, A Boukhris, P Byrne, C Goizet, A Hamri, A Benomar, ...
The American Journal of Human Genetics 82 (4), 992-1002, 2008
Health‐related quality of life in multiple sclerosis: effects of natalizumab
RA Rudick, D Miller, S Hass, M Hutchinson, PA Calabresi, C Confavreux, ...
Annals of neurology 62 (4), 335-346, 2007
REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31
C Beetz, R Schüle, T Deconinck, KN Tran-Viet, H Zhu, BPH Kremer, ...
Brain 131 (4), 1078-1086, 2008
Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases
KP Bhatia, A Münchau, PD Thompson, M Houser, VS Chauhan, ...
Journal of Neurology, Neurosurgery & Psychiatry 67 (1), 90-93, 1999
Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
KET O'Rourke, M Hutchinson
Multiple Sclerosis Journal 11 (1), 46-50, 2005
Systém momentálně nemůže danou operaci provést. Zkuste to znovu později.
Články 1–20